Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Liabilities and Shareholders Equity: 2014-2024

Historic Liabilities and Shareholders Equity for Viking Therapeutics (VKTX) over the last 11 years, with Dec 2024 value amounting to $908.3 million.

  • Viking Therapeutics' Liabilities and Shareholders Equity fell 21.16% to $739.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 billion, marking a year-over-year increase of 3.78%. This contributed to the annual value of $908.3 million for FY2024, which is 146.50% up from last year.
  • According to the latest figures from FY2024, Viking Therapeutics' Liabilities and Shareholders Equity is $908.3 million, which was up 146.50% from $368.5 million recorded in FY2023.
  • In the past 5 years, Viking Therapeutics' Liabilities and Shareholders Equity registered a high of $908.3 million during FY2024, and its lowest value of $168.5 million during FY2022.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $368.5 million (2023), whereas its average is $481.8 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first declined by 20.00% in 2022, then skyrocketed by 146.50% in 2024.
  • Over the past 5 years, Viking Therapeutics' Liabilities and Shareholders Equity (Yearly) stood at $256.5 million in 2020, then decreased by 17.87% to $210.7 million in 2021, then dropped by 20.00% to $168.5 million in 2022, then skyrocketed by 118.65% to $368.5 million in 2023, then surged by 146.50% to $908.3 million in 2024.